Table 3 Functional recovery of severe patients
From: SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection
No./total No. (%) or median (IQR) | |
|---|---|
Pulmonary function test findings (n = 11) | |
Abnormal findings | 6 (54.4) |
FVC, L | 3.40 (3.06–4.03) |
% of predicted | 94.1 (83.5–99.0) |
<80% of predicted | 2 (18.2) |
FEV1, L | 2.91 (2.49–3.42) |
% of predicted | 94.3 (85.3–101) |
<80% of predicted | 1 (9.1) |
FEV1/FVC, % | 84.5 (82.1–85.7) |
<70% | 0 (0) |
DLCO, mmol/kPa/min | 7.08 (6.31–8.36) |
% of predicted | 81.8 (73.2–89.2) |
<80% of predicted | 4 (36.4) |
DLCO/VA, mmol/kPa/min/L | 1.50 (1.40–1.57) |
% of predicted | 95.4 (88.2–104) |
<80% of predicted | 1 (9.1) |
Current abnormal CT findings | 7 (63.6) |
Current respiratory symptoms | 9 (81.8) |
Six-minute walk test (n = 13) | |
Distance, m | 545 (518–625) |
% of predicted | 93.8 (79.3–97.9) |
<lower limit of normal range | 0 (0) |
mMRC dyspnea scale (n = 19) | |
0 | 17 (89.5) |
1 | 1 (5.3) |
2 | 1 (5.3) |
Heart abnormalities | |
Abnormal electrocardiogram | 3/19 (15.8) |
Abnormal echocardiography | 6/19 (31.6) |
Reduced LV diastolic function | 6/19 (31.6) |
Valve disfunction | 2/19 (10.5) |
Abnormal cardiac MRI | 4/6 (66.7) |
LV fibrosis (LGE) | 2/6 (33.3) |
Left atrial enlargement | 3/6 (50) |
Right atrial enlargement | 1/6 (16.7) |
LV hypertrophy | 1/6 (16.7) |
Reduced LV ejection fraction | 0/6 (0) |
Taking antihypertensives | 6/19 (31.6) |
SBP = 130 mmHg or higher | 4/19 (21.1) |
DBP = 80 mmHg or higher | 7/19 (36.8) |
Blood test findings (n = 19) | |
Complete blood count findings | 2 (10.5) |
RBC < 4.3 × 109/L | 2 (10.5) |
Hemoglobin < 30 g/L | 2 (10.5) |
Inflammation-related findings | 2 (10.5) |
hs-CRP > 0.5 mg/L | 0 (0) |
Transferrin < 2.3 g/L | 2 (10.5) |
BNP > 100 pg/mL | 1 (5.3) |
D-dimer > 0.55 mg/L | 0 (0) |
Liver-related findings | 2 (10.5) |
High alanine transaminasea | 2 (10.5) |
High aspartate transaminasea | 1 (5.3) |
Kidney-related findings | 4 (21.1) |
High creatininea | 3 (15.8) |
High ureaa | 2 (10.5) |
